Sun Profit Dives On Ranbaxy Merger Costs
This article was originally published in PharmAsia News
Executive Summary
Sun Pharmaceutical Industries, India’s biggest drug maker by sales, has reported a 30% drop in quarterly net profit from a year earlier, undershooting analysts’ expectations for a third straight trimester and reflecting in part the costs of digesting its merger with Ranbaxy.